<?xml version='1.0' encoding='utf-8'?>
<document id="24900709"><sentence text="Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor."><entity charOffset="28-37" id="DDI-PubMed.24900709.s1.e0" text="serotonin" /><entity charOffset="42-56" id="DDI-PubMed.24900709.s1.e1" text="norepinephrine" /><pair ddi="false" e1="DDI-PubMed.24900709.s1.e0" e2="DDI-PubMed.24900709.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24900709.s1.e0" e2="DDI-PubMed.24900709.s1.e1" /></sentence><sentence text="The objective of the described research effort was to identify a novel serotonin and norepinephrine reuptake inhibitor (SNRI) with improved norepinephrine transporter activity and acceptable metabolic stability and exhibiting minimal drug-drug interaction"><entity charOffset="71-80" id="DDI-PubMed.24900709.s2.e0" text="serotonin" /><entity charOffset="85-99" id="DDI-PubMed.24900709.s2.e1" text="norepinephrine" /><entity charOffset="140-154" id="DDI-PubMed.24900709.s2.e2" text="norepinephrine" /><pair ddi="false" e1="DDI-PubMed.24900709.s2.e0" e2="DDI-PubMed.24900709.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24900709.s2.e0" e2="DDI-PubMed.24900709.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24900709.s2.e0" e2="DDI-PubMed.24900709.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24900709.s2.e1" e2="DDI-PubMed.24900709.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24900709.s2.e1" e2="DDI-PubMed.24900709.s2.e2" /></sentence><sentence text=" We describe herein the discovery of a series of 3-substituted pyrrolidines, exemplified by compound 1"><entity charOffset="49-75" id="DDI-PubMed.24900709.s3.e0" text="3-substituted pyrrolidines" /></sentence><sentence text=" Compound 1 is a selective SNRI in vitro and in vivo, has favorable ADME properties, and retains inhibitory activity in the formalin model of pain behavior" /><sentence text=" Compound 1 thus represents a potential new probe to explore utility of SNRIs in central nervous system disorders, including chronic pain conditions" /><sentence text=" " /></document>